ITCI: Rega marang dodolan Intra-Cellular
The implementation of "green chemistry" principles for environmental protection is complemented by basic compliance with laboratory waste disposal standards for Intra-Cellular Therapies (ITCI). The P/S ratio history on the GURU.Markets chart visualizes this process, where 20.60 serves as the current metric level. Business stability is supported by international biocomponent logistics and the diversification of research centers, ensuring high long-term profitability for the company.
Rincian metrik lan analitis perusahaan Intra-Cellular Therapies (ITCI)
- rega pasar lan target rega analis:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Intra-Cellular Therapies|ITCI - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas intracellulartherapies.com|ITCI - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Intra-Cellular|ITCI - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Intra-Cellular Therapies|Rasio jangkoan perantara intracellulartherapies.com
- rincian asil keuangan lan kelipatan valuasi:
ITCI - Penghasilan resik|Bathi resik mangsa ngarep Intra-Cellular Therapies|ITCI - Pangali P/E|Pangali mangsa ngarep rega marang bathi intracellulartherapies.com|ITCI - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Intra-Cellular|ITCI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Intra-Cellular Therapies|ITCI - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan intracellulartherapies.com|ITCI - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Intra-Cellular Therapies
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:ITCI Intra-Cellular Therapies Inc.
The P/S multiple relates market capitalization to sales volume, reflecting investor expectations regarding the business's future sector share. Analyzing the divergence of the P/S from its historical average allows for the identification of asset overvaluation, which is critical for Intra-Cellular Therapies (ITCI), where the high stock price is justified by colossal R&D expenditures and the potential for leadership in neurobiology.
Pesaing Intra-Cellular Therapies
Kapitalisasi marang pendapatan biogen.com BIIB|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Rega marang dodolan|AXSM - Rasio rega marang pendapatan|ACAD: Rasio rega marang pendapatan|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|VKTX (vikingtherapeutics.com) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan SUPN|Multiplikator P/S Catalyst Pharma|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|Rasio rega marang pendapatan HRMY (Harmony Corp)|Multiplikator P/S BHVN (Biohaven Ltd.)|Multiplikator P/S amylyx.com AMLX|TRVI - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRAX (Praxis Precision Medicines Inc)|AVXL (Anavex Corp) - Kapitalisasi marang pendapatan|CeriBell EEG - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan PRTA|ALEC (Alector Therapeutics) - Kapitalisasi marang volume dodolan|Multiplikator P/S ANNX|OMER (omeros.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Rega marang dodolan|VYGR - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan NMRA (neumoratx.com)|SCLX: Multiplikator P/S|Tevogen Bio Holdings Inc. (TVGN) - Multiplikator P/S|Rasio rega marang pendapatan Alpha Cognition Inc|Cognition Therapeutics Inc. - Rasio rega marang dodolan|Multiplikator P/S IKT|Koefisien rega marang pendapatan cassavasciences.com|Multiplikator P/S ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Rega marang dodolan|VTGN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Ovid Therapeutics Inc. OVID|ABOS: Multiplikator P/S|CRVO - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan ATHE|CLNN (Clene Nanomedicine) - Kapitalisasi marang volume dodolan|Multiplikator P/S PEPG|Kapitalisasi marang pendapatan Jupiter Neurosciences, Inc. JUNS|Multiplikator P/S RLMD (Relmada Therapeutics)|Koefisien rega marang pendapatan annovisbio.com (ANVS)|GRCE - Rasio rega marang pendapatan|AIFF (Firefly Neuroscience, Inc.) - Rasio kapitalisasi marang pendapatan|KLTO: Multiplikator P/S|Rega marang dodolan NeuroSense Therapeutics Ltd. (NRSN)|Kapitalisasi marang pendapatan RVPH|Multiplikator P/S MetaVia, Inc.|Rasio rega marang pendapatan NeurAxis (NRXS)|HSDT (heliusmedical.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Rega marang dodolan|Minerva Neurosciences - Multiplikator P/S|Koefisien rega marang pendapatan athira.com ATHA|Addex Therapeutics Ltd (ADXN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan ALZN|Kapitalisasi marang pendapatan CYCN|PTIX (Protagenic) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ATXI (Avenue Therapeutics, Inc.)|Multiplikator P/S Brainstorm Cell Therapeutics Inc. BCLI|CARA: Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Chromocell (CHRO)|ELYM: Multiplikator P/S|Kapitalisasi marang pendapatan longboardpharma.com|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|Rega marang dodolan NKGen Biotech Inc NKGN|Rasio rega marang pendapatan NeuroBo (NRBO)|Rasio rega marang pendapatan SAGE (Sage Therapeutics Inc)|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|trevena.com - Rasio rega marang pendapatan|VIGL: Kapitalisasi marang pendapatan|WENA - Multiplikator P/S|Cerevel (CERE) - Rasio rega marang pendapatan
